Skip to content

Press Releases

XIFIN Joins Personalized Medicine Coalition

New membership expands company’s advocacy role

XIFIN Inc., the leading provider of revenue cycle management for diagnostic service providers, has joined the Personalized Medicine Coalition, (PMC) an educational and advocacy group dedicated to advancing the understanding and adoption of personalized medicine, defined as the application of genomic and molecular data to better target the delivery of healthcare by determining a person's predisposition to a particular disease or condition.

XIFIN’s service model includes partnership and advocacy on behalf of both early stage and leading laboratories and molecular diagnostic companies involved in technologies that advance personalized medicine. The company actively participates in the development of key open standards within the industry including Health Level 7 (HL7), the Workgroup for Electronic Data Interchange (WEDI) and the HIPAA 5010 format. As an advocate for practices and policies that affect diagnostic services, XIFIN is a long standing member of various industry organizations like the American Clinical Laboratories Association (ACLA) and California Clinical Laboratory Association (CCLA).

“The PMC allows a variety of stakeholders to work together to understand the challenges and issues impacting the advancement of personalized medicine,” said Lale White, CEO of XIFIN. “The current regulatory and reimbursement environment can be slow to recognize the uniqueness of diagnostics that support personalized medicine. It is XIFIN’s goal to work with the PMC to help evolve reimbursement policies and practices that are supportive of personalized medicine and better reflect their value.”

The coalition is comprised of academic, industrial, patient, provider and payer organizations promoting the understanding and adoption of personalized medicine through a number of initiatives. Since its launch in 2004, the coalition has provided leadership and a forum for education and advocacy for the public, policymakers, government officials and private sector healthcare leaders to further the public interest in personalized medicine.

Contacts:
Bill Taylor
Vice President, Marketing
XIFIN, Inc.
858.436.2995
btaylor@xifin.com

Myla Wagner
Myla Wagner Public Relations
925.736.7515
myla@mylawagnerpr.com

About XIFIN

XIFIN is a next-generation, cloud-based, revenue cycle management system that maximizes cash collection, improves operational efficiency, increases profit and reduces the risks associated with regulatory compliance with a compelling return on investment and rapid time-to-value. The company has received continual industry recognition, including being named to the Inc. 5000 fastest growing privately-held companies 2007 through 2011, and ranking among Deloitte’s Technology Fast 500. To learn how XIFIN uniquely delivers revenue cycle management, visit www.XIFIN.com, or follow XIFIN on Twitter at www.twitter.com/#!/xifin.